Home | Welcome to Contract Pharma   
Last Updated Saturday, May 23 2015


Financial Report: Alexion

Published February 14, 2013

4Q Revenues: $320.5 million (+41%)

4Q Earnings: $81.0 million (+68%)

FY Revenues: $1.1 billion (+45%)

FY Earnings: $254.8 million (+45%)

Comments: Soliris sales were $320.5 million in the quarter, up 41%, and $1.1 billion for the year, up 45% driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS).

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On